Moderna, Inc.

Tweet this page
<
2021
2022
2023
2024
>
Registration as it was on 24 Feb 2021
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

150,000€

Financial year: Jan 2020 - Dec 2020

Lobbyists (Full time equivalent)

0.25 Fte (1)

Lobbyists with EP accreditation

0

High-level Commission meetings

4

Lobbying Costs over the years

  • Info

    Moderna Inc.

    EU Transparency Register

    011080341579-06 First registered on 24 Feb 2021

    Goals / Remit

    Moderna’s mRNA technology quickly enabled us to pivot when the COVID-19 crisis emerged and to manufacture and deliver a safe, effective vaccine against COVID-19. In this context, Moderna made two agreements with the European Commission for Advance Purchase Agreements. The pioneering technology in our vaccine will be offered soon in other cures and therapies such as immuno-oncology, which will continue to deliver benefits to European citizens and see mRNA technology support new initiatives such as Europe’s Beating Cancer Plan.

    Main EU files targeted

    Moderna’s mRNA technology quickly enabled us to pivot when the COVID-19 crisis emerged and to manufacture and deliver a safe, effective vaccine against COVID-19. In this context, Moderna made two agreements with the European Commission for Advance Purchase Agreements. The pioneering technology in our vaccine will be offered soon in other cures and therapies such as immuno-oncology, which will continue to deliver benefits to European citizens and see mRNA technology support new initiatives such as Europe’s Beating Cancer Plan.

    Address

    Head Office
    200 Technology Square
    Cambridge 02139
    UNITED STATES
  • People

    Total lobbyists declared

    1

    Employment timeLobbyists
    25%1

    Lobbyists (Full time equivalent)

    0.25

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 24 Feb 2021

    Name Start date End Date
    Maren DR. VON FRITSCHEN 18 Jan 2024 17 Jan 2025
    Mr Alexander DR. MEIER 18 Jan 2024 17 Jan 2025

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    https://www.vaccineseurope.eu

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2020 - Dec 2020

    Lobbying costs for closed financial year

    150,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    None

    Other activities

    None declared

  • Meetings

    Meetings

    4 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    • Date 03 Nov 2022 Location Bruxelles
      Subject Videoconference with Moderna CEO on future of mRNA platform; ongoing cooperation on the management of the pandemic
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Attending
      • Daphne von Buxhoeveden (Cabinet member)
      • Stella Kyriakides (Commissioner)
    • Date 26 Nov 2021 Location Videoconference
      Subject Meeting with CEO of Moderna
      Cabinet Cabinet of President Ursula von der Leyen
      Portfolio President
      Attending
      • Ursula von der Leyen (President)
    • Date 10 Apr 2021 Location Videocall
      Subject Vaccine production and deliveries
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Thierry Breton (Commissioner)
      Other Lobbyists
    • Date 31 Jan 2021 Location Videoconference
      Subject Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements
      Cabinet Cabinet of President Ursula von der Leyen
      Portfolio President
      Attending
      • Ursula von der Leyen (President)
      Other Lobbyists
Download this datacard